Sector News

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

May 21, 2022
Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence.

The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

Moderna’s board chairman Noubar Afeyan, speaking with The Financial Times, said legalities prevented Dentsply Sirona from revealing its probe into financial reporting inaccuracies.

“Both the process of recruiting and vetting and the process with which we reacted to the new facts that came out, were completely appropriate,” Afeyan told FT. “I can’t think of a different approach that we could have used under those circumstances.”

Dentsply’s investigation was triggered by information from previous and current employees. The company then notified the SEC of its internal probe.

Moderna announced the hire of Gomez on April 11 to replace retiring CFO David Meline. Eight days later, Dentsply Sirona revealed the immediate and unexplained departure of its CEO Don Casey.

Casey, formerly the CEO of the medical segment of Cardinal Health, arrived at Dentsply in 2018. A year later he hired Gomez, who was the CFO at Cardinal for 13 years.

Gomez’ first day at Moderna was May 10. The company revealed his departure the following day.

On Monday, Moderna said it would attempt to claw back Gomez’ $700,000 severance package, equal to a year’s salary, if he is found of wrongdoing or is fined by the SEC.

As Moderna has rapidly evolved from its previous identity as a small biotech to a global vaccine power, it has had growing pains and executive changes.

“The scale that they’ve achieved and the growth is completely commensurate with the leadership changes,” Afeyan told the Times.

By Kevin Dunleavy

Source: fiercepharma.com

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach